BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
8/20/2025 8:41:24 AM | Browse: 323 | Download: 1108
Publication Name World Journal of Clinical Oncology
Manuscript ID 109419
Country China
Received
2025-05-12 08:55
Peer-Review Started
2025-05-12 08:55
First Decision by Editorial Office Director
2025-05-20 18:55
Return for Revision
2025-05-21 15:15
Revised
2025-05-25 14:52
Publication Fee Transferred
2025-05-26 08:01
Editorial Processing by Scientific Editor
2025-07-02 02:38
Final Academic Decision by Editor-in-Chief
Publication Technical Verification by Editorial Office Director
2025-07-02 06:29
Articles in Press
2025-07-02 06:29
Edit the Manuscript by Language Editor
Typeset the Manuscript
2025-08-07 02:48
Publish the Manuscript Online
2025-08-20 08:41
ISSN 2218-4333 (online)
Open Access This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright © The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Gastroenterology & Hepatology
Manuscript Type Retrospective Study
Article Title Combination therapy reduces transarterial chemoembolization resistance in advanced hepatocellular carcinoma
Manuscript Source Unsolicited Manuscript
All Author List Hu-Yu Jiao, Xin-Mei Yan, Jun-Xin Li and Zhen-Gang Zhang
ORCID
Author(s) ORCID Number
Zhen-Gang Zhang http://orcid.org/0009-0002-7888-973X
Funding Agency and Grant Number
Corresponding Author Zhen-Gang Zhang, MD, PhD, Department of Gastroenterology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 1095 Jiefang Avenue, Wuhan 430000, Hubei Province, China. zgzhang@tjh.tjmu.edu.cn
Key Words Transarterial chemoembolization; Programmed death-ligand 1; Molecular targeted therapy; Hepatocellular carcinoma; Drug resistance
Core Tip This study demonstrates that combining transarterial chemoembolization (TACE) with programmed cell death (ligand) 1 inhibitors and molecular targeted therapy significantly reduces TACE resistance and improves survival in advanced hepatocellular carcinoma. The combination therapy prolongs progression-free survival and overall survival. Additionally, the study identifies maximum tumor diameter, tumor capsule integrity, and bilobar distribution of tumor as key factors influencing TACE resistance, providing new insights for optimizing treatment strategies.
Publish Date 2025-08-20 08:41
Citation

Jiao HY, Yan XM, Li JX, Zhang ZG. Combination therapy reduces transarterial chemoembolization resistance in advanced hepatocellular carcinoma. World J Clin Oncol 2025; 16(8): 109419

URL https://www.wjgnet.com/2218-4333/full/v16/i8/109419.htm
DOI https://dx.doi.org/10.5306/wjco.v16.i8.109419
Full Article (PDF) WJCO-16-109419-with-cover.pdf